When Your Child's Medication Is Denied: Step Therapy and the Pediatric Difference
When Your Child's Medication Is Denied: Step Therapy and the Pediatric Difference
You took your child to a specialist. The specialist, who has seen your child for months or years and knows their history, prescribed a specific medication. And then the insurance company said no, not yet. They need to try something else first.
This is step therapy, and when it is applied to children, it creates a different set of problems than when it is applied to adults. The standard arguments that work in adult step therapy appeals sometimes do not map cleanly onto pediatric cases. The clinical stakes can be higher. The treatment windows are narrower. And there are specific legal protections in some states that apply only to children.
If you are navigating a step therapy denial for your child, this is what you need to know.
Why Pediatric Step Therapy Is Different
Step therapy protocols were developed primarily based on adult clinical trial data and adult treatment guidelines. Most evidence-based medicine research is conducted in adults, partly because pediatric clinical trials are harder to conduct and partly because regulatory pathways for pediatric indications developed later than for adult ones.
When an insurer applies a step therapy protocol to a child, they are often applying adult-derived criteria to a patient population for which those criteria were not designed. There are several specific ways this creates clinical problems.
Failure thresholds don't translate. In adult step therapy for rheumatoid arthritis, a protocol might require failure of two DMARDs (disease-modifying antirheumatic drugs) before a biologic is authorized. In pediatric patients with juvenile idiopathic arthritis (JIA), the treatment guidelines from the American College of Rheumatology specify different criteria, because the disease course, the available evidence, and the acceptable risk of treatment delay are not the same.¹
Treatment windows close faster. For conditions involving neurological development, joint damage, or growth, delays of even a few months can have consequences that are permanent in ways they would not be for adults with the same condition. A child with untreated inflammatory arthritis faces joint damage during growth years. A child with poorly controlled epilepsy faces developmental risks from uncontrolled seizures. A child with treatment-resistant depression faces risks to educational development and social functioning. The calculus for "try this first" is different when developmental windows are involved.
Children cannot be their own advocates. Adults navigating step therapy can describe their symptoms, make decisions about treatment risks, and drive the appeal process themselves. Children depend entirely on parents, caregivers, and providers to advocate for them. This creates additional cognitive and logistical burden on families who are already dealing with a sick child.
What Arguments Work in Pediatric Step Therapy Appeals
When you file an appeal of a step therapy denial for your child, the goal is to document why the standard step therapy protocol is clinically inappropriate for your specific child. Here are the arguments that are most effective.
Pediatric-specific treatment guidelines. Many major pediatric professional societies, including the American Academy of Pediatrics, the American College of Rheumatology Pediatric Rheumatology section, the American Academy of Child and Adolescent Psychiatry, and the Crohn's and Colitis Foundation, have published treatment guidelines specific to pediatric patients that differ from adult guidelines. If your child's prescribed medication is consistent with the relevant pediatric clinical guideline and the step therapy protocol is not, that is a strong medical necessity argument.
Ask your child's specialist to cite the specific pediatric guideline in the appeal letter and explain how the insurer's step therapy protocol deviates from it.
Prior treatment failure under a previous plan. If your child has already tried and failed the required step therapy medication under a previous insurer or at any prior point in their treatment, you should not have to repeat that failure. Most states with step therapy laws have provisions for prior treatment failure, and CMS guidance on Medicare step therapy (while not directly applicable to commercial plans) recognizes this principle. Document the prior failure in writing from the treating physician.
Current stability. If your child is currently stable on a medication that the insurer is requiring them to switch away from, stability is a medical necessity argument. Forcing a stable patient off a medication that is working, to undergo step therapy for a new insurer, creates risk without clinical benefit. Many state step therapy laws include continuity of care provisions that specifically address this.²
Developmental risk from delay. Ask your child's specialist to document, in explicit language, the developmental, neurological, or functional consequences of a treatment delay in your child's specific case. Language like "a delay of 30 to 90 days in initiating this therapy poses a significant risk of permanent joint damage given this patient's age and growth trajectory" is more useful in an appeal than general language about medical necessity. The more specific and quantified the harm from delay, the stronger the appeal.
FDA approval or pediatric label. If the prescribed medication has FDA approval for use in the pediatric population for your child's diagnosis, document it. Some insurers apply step therapy protocols that do not account for pediatric indications, and pointing out that the medication has a specific FDA-approved pediatric indication can be helpful.
States With Pediatric Step Therapy Exceptions
Several states have enacted step therapy legislation with specific provisions protecting pediatric patients. The details vary by state, but these are the general categories of pediatric-specific protections to look for.
Reduced or eliminated step therapy requirements for children under a certain age. Some state laws specifically reduce the number of required prior treatment failures for pediatric patients, or eliminate step therapy requirements for children under a specified age for certain condition categories.
Mandatory exceptions for children with serious or chronic conditions. Some state laws require insurers to grant automatic step therapy exceptions for children who have a documented serious, chronic, or life-threatening condition and whose prescribing physician has documented why the required step therapy is clinically inappropriate.
Developmental and functional harm documentation standards. Some state laws explicitly require insurers to consider the developmental impact of treatment delay when evaluating step therapy exception requests for pediatric patients.
States that have enacted some form of step therapy reform legislation with provisions that may protect pediatric patients include Texas, New York, Florida, Arkansas, Maryland, Virginia, Illinois, and others.² The National Conference of State Legislatures (NCSL) maintains a tracker of enacted step therapy legislation that includes the specific provisions of each state's law.³ It is worth reviewing your state's specific law with your insurer's plan documents to understand what protections apply.
If you are in an ERISA-governed employer plan, state step therapy laws may not apply directly to your plan, but the pediatric clinical arguments remain valid in the federal appeals process.
What Your Child's Specialist Should Include in the Appeal Letter
The appeal letter from your child's treating physician or specialist carries the most weight in a step therapy exception request. When you ask your child's doctor to write the letter, here is what the most effective letters include.
Specific diagnosis with ICD code. The diagnosis code ties the clinical argument to the specific condition and the specific medication being requested.
Statement of medical necessity tied to the patient's age, development, and disease stage. Not just "this medication is medically necessary" but why it is necessary for this child at this age at this stage of their disease. The more specific, the better.
Reference to relevant pediatric clinical guidelines. Cite the specific guideline, the publishing organization, and how the prescribed medication aligns with it. Note if the insurer's step therapy protocol deviates from the guideline.
Prior treatment history. Every medication the child has already tried, with dates and documented outcomes. If any prior step therapy medications were tried and failed, document the failure and the nature of the adverse response or inadequate response.
Consequences of further delay. Specific, patient-specific language about what a delay means for this child's development, function, or disease course.
Statement about clinical inappropriateness of the required step therapy medication. If the required step therapy medication is contraindicated, has documented inadequate efficacy in pediatric patients with this condition, or creates specific risks that do not apply to the prescribed medication, that needs to be stated explicitly.
The Practical Steps
When you receive a step therapy denial for your child, here is the sequence that tends to be most effective.
First, call your child's specialist's office the same day. Do not wait. Ask specifically whether they can initiate a peer-to-peer review with the insurer's medical director. Many step therapy denials are resolved at this stage without a formal appeal.
Second, request the specific denial reason code and the step therapy criteria the insurer used. You have the right to this information under ERISA and ACA appeals regulations.
Third, if peer-to-peer review does not resolve it, work with your child's specialist to file a formal internal appeal. The letter should include everything described in the section above. You have the right to submit additional documentation, and your child's medical records, specialist notes, and any relevant published pediatric guidelines are all fair game.
Fourth, if the internal appeal fails, request external review. External review is binding on your insurer, and external reviewers are often more receptive to pediatric clinical arguments that point out the mismatch between adult step therapy protocols and pediatric clinical standards.
Fifth, check whether your state has a step therapy law with pediatric provisions, and whether that law applies to your plan type.
What This Means for You
Your child's specialist knows their patient. A step therapy protocol designed for adults does not automatically translate to your child's situation, and you have the right to challenge it when it doesn't.
The appeal process is worth pursuing. The AMA's 2024 survey data shows that prior authorization requests, including step therapy exceptions, are approved at high rates when a complete appeal is submitted with adequate documentation.⁴ The key is knowing what documentation is most persuasive and making sure your child's physician has included it.
Ellen can help you decode your child's denial letter, identify the specific step therapy basis for the denial, and prepare a summary of what an effective appeal letter should include to bring to your child's next appointment.
Frequently Asked Questions
Does step therapy apply to all children's medications?
Step therapy is most commonly applied to specialty medications for chronic conditions: biologics for inflammatory conditions, certain medications for behavioral health and neurological conditions, and brand-name medications where generic equivalents exist. Not all children's prescriptions are subject to step therapy.
What if my child has a rare condition with no standard step therapy options?
Rare conditions often have no therapeutic alternatives for step therapy to require, which is one of the strongest arguments for an immediate exception. The prescribing physician should document this explicitly and reference the relevant orphan drug designation or rare disease clinical literature.
Can I request that my insurer waive step therapy based on my child's age?
Yes. In states with pediatric step therapy protections, you can explicitly invoke those protections. In any state, the clinical argument that an adult step therapy protocol is not appropriate for a pediatric patient is a valid appeal argument.
What if we are between insurance plans and need to restart step therapy for a new insurer?
If your child has previously completed the required step therapy and failed, document that history with medical records and ask your child's physician to attest to it in the appeal letter. Prior failure of the required step therapy medication is one of the strongest grounds for an exception under most state laws and federal appeals standards.
Sources
Ellen can help you understand your child's denial and prepare the documentation framework for your specialist's appeal letter. Start at EllenRx.com.